# FOXO4-DRI Peptide

> FOXO4-DRI is a D-retro-inverso peptide that disrupts FOXO4-p53 binding in senescent cells and targets senolytic aging pathways.

Canonical: https://pepflow.app/peptides/foxo4-dri/

The Senolytic Probe

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4-p53 interaction in senescent cells. It is discussed as a senolytic research peptide.

Cellular aging

Tier E

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 22 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is FOXO4-DRI?

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4-p53 interaction in senescent cells. It is discussed as a senolytic research peptide.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)

The strongest evidence is preclinical aging and senescence biology. Human anti-aging or disease-treatment outcomes are not established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)

Senolytic language is high-risk because clearing senescent cells sounds compelling but can affect tissue repair, cancer biology, immune status, and frailty differently across people.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)

## What FOXO4-DRI is investigated for

FOXO4-DRI evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Senescent-cell clearance Injectable 30% Limited

Senescent-cell clearance is the core FOXO4-DRI claim, but it remains preclinical.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)

#### Human evidence

Human FOXO4-DRI senolytic outcome trials are not established in the cited literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)

#### Animal / mechanistic evidence

Mouse and molecular studies support targeted apoptosis of senescent cells through FOXO4-p53 disruption.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)

### ### Age-related tissue and physical function Injectable 28% Limited

Age-related tissue-function claims are model-based senolytic biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/33996787/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/39994346/>)

#### Human evidence

Human age-related tissue-function outcomes are not established in the cited literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/33996787/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/39994346/>)

#### Animal / mechanistic evidence

Aging and chondrocyte-model studies support tissue-homeostasis and tissue-function hypotheses.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/33996787/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/39994346/>)

### ### Inflammatory tissue remodeling Injectable 24% Limited

Inflammatory tissue remodeling is a lower-confidence biology signal with important context-dependent risk.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/39994346/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/29260442/>)

#### Human evidence

Human chronic-inflammation outcome evidence for FOXO4-DRI is not established in the cited literature.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/39994346/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/29260442/>)

#### Animal / mechanistic evidence

Keloid fibroblast, kidney senescence, and pulmonary-hypertension literature show that senescent-cell targeting can cut both ways by tissue context.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/39994346/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/29260442/>)

## Evidence snapshot

### Overall confidence

Limited

30%

FOXO4-DRI remains a preclinical senolytic concept. Human anti-aging outcomes, dose-ranging, and tissue-specific safety are not established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

10%

### Human evidence

Insufficient

Human senolytic or anti-aging outcomes are not established for FOXO4-DRI.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

20%

### Animal / preclinical

Limited

Animal and cell studies support the FOXO4-p53 senescence rationale.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

30%

### Mechanism support

Limited

FOXO4-DRI is intended to disrupt a survival interaction in senescent cells, allowing p53-mediated apoptosis. The concept is senescent-cell removal, not a validated human rejuvenation protocol.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## Forms & administration

FOXO4-DRI is tracked as an injectable senolytic research-market peptide. Intermittent senolytic protocol patterns are separate from approved anti-aging or oncology claims.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

No human dose has been established. Injectable protocols commonly start at 250 mcg.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

### Frequency

Common schedules use 3 doses per week.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

### Timing Considerations

Morning is the usual timing, with doses spaced across the week.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

### Cycle Length

Common cycles run 3 weeks.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

[Full FOXO4-DRI dosage guide](<https://pepflow.app/peptides/foxo4-dri/dosage/>)

## What to expect

### First 1-2 weeks

Injectable FOXO4-DRI senolytic-style cycles may feel like changes in energy, recovery, inflammatory symptoms, or tissue-repair comfort.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>)

### Weeks 4-8

Injectable senolytic-style cycles may leave clearer recovery feel, inflammatory-symptom, energy, or lab-pattern changes after the short cycle.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>)

### After stopping

Any injectable FOXO4-DRI senolytic-style signal may persist beyond exposure, so energy and recovery patterns can continue changing after the cycle.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>)

## Safety profile

FOXO4-DRI safety centers on senolytic-pathway uncertainty, tissue-repair context, immune/cancer history, and injectable product quality.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

### Cautions

- Off-target senolysis[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)
- Wound / tissue repair[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)
- Cancer / immune disease[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)
- Product quality[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

### What we don't know

Human dose-ranging, tissue specificity, durability of senolytic effects, immune consequences, and long-term safety remain unclear.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## Who FOXO4-DRI is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for FOXO4-DRI.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)
- **Active cancer or recent cancer treatment without specialist review**

  Active cancer or recent cancer treatment without specialist review warrants medical review or avoidance for FOXO4-DRI.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)
- **Active wounds or major surgery recovery without clinician oversight**

  Active wounds or major surgery recovery without clinician oversight warrants medical review or avoidance for FOXO4-DRI.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Senolytic stacks**

  Dasatinib, quercetin, fisetin, or other senolytic products can stack cell-clearance effects and adverse-event attribution; this is a theoretical pathway caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)
- **Oncology / immune therapies**

  Chemotherapy, targeted cancer therapy, checkpoint inhibitors, or immune biologics can make cell-cycle and immune effects difficult to attribute; this is a theoretical pathway caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)
- **Anticoagulants / antiplatelets**

  Warfarin, DOACs, aspirin, or antiplatelet therapy can increase the consequence of injection bruising or bleeding symptoms; this is a route-specific caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, FOXO4-DRI has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · FOXO4-DRI is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Not Listed · FOXO4-DRI is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Not Approved

FOXO4-DRI is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Not Listed

FOXO4-DRI is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[15\]](<https://www.ema.europa.eu/en/medicines>) [\[16\]](<https://products.mhra.gov.uk/>) [\[17\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[18\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat FOXO4-DRI injectable route as athlete-cleared without sport-specific review.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

FOXO4-DRI is designed to disrupt the FOXO4-p53 survival interaction in senescent cells, allowing p53-mediated apoptosis. In plain terms, the goal is to help damaged, non-dividing cells self-remove instead of persisting in tissue.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

Systemic injectable exposure makes that biology a safety problem as well as an opportunity. Senescent cells can participate in wound healing and tissue remodeling, so broad removal claims need human dose, timing, tissue-selectivity, and safety data. The systemic route raises distribution, timing, and off-target questions that cell experiments cannot answer.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## Research gaps & open questions

What the current literature has not yet settled about FOXO4-DRI:

01

No human studies have established which dose reaches the intended tissues, how long FOXO4-DRI stays in the body, or which dose is tolerable.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

02

Because senescent cells also help with some repair processes, studies need to show whether clearing them can delay wound healing or harm recovering tissue.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

03

Human trials need to show whether FOXO4-DRI actually reduces senescent cells and improves strength, mobility, cognition, or other day-to-day function.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## Common questions

### Is FOXO4-DRI FDA-approved?

No. FOXO4-DRI is not FDA-approved in the U.S. for injectable drug use, and research-market products are not FDA-approved.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

### Is FOXO4-DRI a senolytic?

Yes. FOXO4-DRI is designed as a senolytic research peptide, but human benefit and systemic injectable safety are not established.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

### Does it reverse aging?

No. Human anti-aging outcomes are not established; senescent-cell biology needs human dose, timing, tissue-selectivity, and safety evidence.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)

## Myths & misconceptions

### Myth

All senescent cells need removal.

### Reality

Senescent cells can have situation-dependent roles in repair and cancer biology.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

### Myth

Preclinical senolytics are ready for routine use.

### Reality

Human dosing, safety, and outcomes are the missing decision points.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## History & discovery

FOXO4-DRI became visible through senescence research that proposed disrupting the FOXO4-p53 interaction to trigger apoptosis in senescent cells. Its history is almost entirely preclinical. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

The landmark preclinical work connected FOXO4 disruption with senescent-cell removal and tissue-homeostasis signals. That milestone created the longevity-market story before human dosing existed.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

Later structural and disease-model work refined the p53 interaction story and showed that eliminating senescent cells can be harmful in some contexts. That changed the history toward caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/28340339/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40593617/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)

## Published research 22 citations

- [\[1\] **Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.** Cell, 2017 Mar 23. animal.](<https://pubmed.ncbi.nlm.nih.gov/28340339/>)
- [\[2\] **The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.** Nat Commun, 2025 Jul 1. review.](<https://pubmed.ncbi.nlm.nih.gov/40593617/>)
- [\[3\] **Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.** Circulation, 2023 Feb 21. animal.](<https://pubmed.ncbi.nlm.nih.gov/36515093/>)
- [\[4\] **Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.** Front Bioeng Biotechnol, 2021. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/33996787/>)
- [\[5\] **FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.** Commun Biol, 2025 Feb 24. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/39994346/>)
- [\[6\] **Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.** Naunyn Schmiedebergs Arch Pharmacol, 2026 Apr 23. review.](<https://pubmed.ncbi.nlm.nih.gov/42024235/>)
- [\[7\] **Cellular senescence in the aging and diseased kidney.** J Cell Commun Signal, 2018 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/29260442/>)
- [\[8\] **Drugs@FDA/openFDA query for FOXO4-DRI** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22FOXO4-DRI%22&limit=1>)
- [\[9\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[10\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[11\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[12\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[13\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[14\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[15\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[16\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[17\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[18\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[19\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[20\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[21\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[22\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Cell-penetrating peptide

**Tier**

E

**Evidence**

30% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Not Listed

**Citations**

[22 citations](<https://pepflow.app/peptides/foxo4-dri/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Senescent-cell clearance
- Age-related tissue and physical function
- Inflammatory tissue remodeling

### Also known as

- FOXO4-D-retro-inverso
- FOXO4-DRI peptide
- FOXO4-p53 disrupting peptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [FOXO4-DRI dosage guide](<https://pepflow.app/peptides/foxo4-dri/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
